Golden Biotechnology Corporation (4132.TWO), a Taiwan-based biopharmaceutical company, has revealed that its Antroquinonol, a new drug intended to treat acute myeloid leukaemia (AML) patients, outperformed other listing drugs in its phase two clinical study conducted in Russia, it was reported on Thursday.
The result indicated higher remission rates and survival rates assuring fewer patients will require blood transfusions. The primary efficacy indicator results demonstrated the overall remission rate of patients with relapsed AML reaches 50%. 80% of patients' abnormal blasts counts in bone marrow or blood reduced to less than 5% after treatment. The secondary outcome measures resulted in the overall survival rate of patients with relapsed AML by 100% at the sixth month after the treatment. The trial was an open-label, non-randomised, Phase 2a study to assess efficacy and safety/tolerability profiles in adult patients with relapsed AML or at initial diagnosis when no intensive treatment is possible
The new drug received orphan drug designation from the US FDA for the treatment of AML in 2015.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial